Search Results 251-260 of 17392 for Interferon

1. A Study to Evaluate the Effectiveness, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera - Mayo Clinic

   Patients previously treated with MDM2 antagonist therapies or patients receiving interferon-alpha, anagrelide, or ruxolitinib within 28 days or 5 half-lives ...

2. A Study to Evaluate Gemcitabine and MK-3475 (Pembrolizumab) to Treat Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - Mayo Clinic

   Patients must not have received any prior or concurrent systemic chemotherapy or immunotherapy (prior intravesical chemotherapy and interferon is permitted).

3. https://www.mayoclinic.org/chinese_organization_concepts.xml

4. A Study to Evaluate the Effectiveness of Spesolimab to Treat Hidradenitis Suppurativa - Mayo Clinic

   Participation eligibility · Patients with active tuberculosis should be excluded; · Patients will be screened with Interferon Gamma Release Assay (IGRA) such as ...

5. Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC) - Mayo Clinic

   Pretreatment with interferon as last treatment prior to start of study treatment. Prior treatment for study indication with: Antibodies or immunotherapy ...

6. Publications - Matthew J. Binnicker, Ph.D. - Mayo Clinic

   Preemployment screening for tuberculosis in a large health care setting: comparison of the tuberculin skin test and a whole-blood interferon-gamma release assay ...

7. A Study Evaluating the Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma - Mayo Clinic

   Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and IL-2) within 6 weeks or 5 half-lives of the drug, whichever is ...

8. JavaScript is disabled. In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.

9. Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer - Mayo Clinic

   ... interferon or other anti-HCV therapy will be excluded from study; Active autoimmune disease or history of autoimmune disease that might recur, which may ...

10. Despite Similarities, NMO and MS Take Different Courses, Require Different Treatments

    Multiple sclerosis often is initially treated with interferon beta medications that work by reducing inflammation. These medications don't help patients ...